BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022.
Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.
Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Adv. 2022.
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015.
Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biol Blood Marrow Transplant. 2015.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016.
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022.
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.
The role of regulatory T cells in graft-versus-host disease management. Expert Rev Hematol. 2019..